| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
123.51(B) |
| Last
Volume: |
1,112,262 |
Avg
Vol: |
1,608,800 |
| 52
Week Range: |
$323.62 - $456.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
34,832 |
156,170 |
271,197 |
631,666 |
| Total Sell Value |
$15,561,839 |
$65,781,555 |
$107,325,701 |
$215,119,054 |
| Total People Sold |
10 |
13 |
14 |
18 |
| Total Sell Transactions |
12 |
45 |
68 |
135 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Silva Paul M |
SVP & Controller |
• – – |
2020-01-31 |
4 |
AS |
$238.65 |
$333,155 |
D/D |
(1,396) |
17,759 |
|
16% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-01-31 |
4 |
OE |
$187.53 |
$261,792 |
D/D |
1,396 |
19,155 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2020-01-31 |
4 |
AS |
$224.03 |
$456,042 |
D/D |
(2,000) |
2,847 |
|
16% |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-01-31 |
4 |
D |
$231.21 |
$310,746 |
D/D |
(1,344) |
33,659 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-01-31 |
4 |
AS |
$238.65 |
$932,883 |
D/D |
(3,909) |
35,003 |
|
16% |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-01-31 |
4 |
OE |
$187.53 |
$733,055 |
D/D |
3,909 |
38,912 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-01-22 |
4 |
AS |
$237.50 |
$238 |
D/D |
(1) |
35,003 |
|
21% |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-01-22 |
4 |
OE |
$187.53 |
$188 |
D/D |
1 |
35,004 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-01-08 |
4 |
AS |
$230.00 |
$1,150,000 |
D/D |
(5,000) |
36,190 |
|
20% |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-01-08 |
4 |
OE |
$109.14 |
$545,700 |
D/D |
5,000 |
41,190 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-01-08 |
4 |
AS |
$231.89 |
$3,188,488 |
D/D |
(13,750) |
17,759 |
|
20% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-01-08 |
4 |
OE |
$131.89 |
$1,813,488 |
D/D |
13,750 |
31,509 |
|
- |
|
| Tatsis Ourania |
SVP, CRO |
• – – |
2020-01-08 |
4 |
AS |
$227.53 |
$381,113 |
D/D |
(1,675) |
7,252 |
|
20% |
|
| Tatsis Ourania |
SVP, CRO |
• – – |
2020-01-08 |
4 |
OE |
$187.53 |
$314,113 |
D/D |
1,675 |
8,927 |
|
- |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-01-06 |
4 |
AS |
$218.93 |
$943,514 |
D/D |
(4,250) |
35,003 |
|
24% |
|
| Parini Michael |
EVP, CL&AO |
• – – |
2020-01-06 |
4 |
OE |
$122.45 |
$520,413 |
D/D |
4,250 |
39,253 |
|
- |
|
| Young William D |
Director |
– • – |
2020-01-02 |
4 |
AS |
$217.72 |
$4,378,696 |
D/D |
(20,000) |
9,311 |
|
30% |
|
| Young William D |
Director |
– • – |
2020-01-02 |
4 |
OE |
$72.14 |
$1,442,800 |
D/D |
20,000 |
29,311 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-01-02 |
4 |
AS |
$217.68 |
$5,610,993 |
D/D |
(25,630) |
17,759 |
|
30% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-01-02 |
4 |
OE |
$86.52 |
$2,623,810 |
D/D |
25,630 |
43,389 |
|
- |
|
| Young William D |
Director |
– • – |
2019-12-30 |
4 |
AS |
$218.05 |
$6,562,715 |
D/D |
(30,000) |
9,311 |
|
30% |
|
| Young William D |
Director |
– • – |
2019-12-30 |
4 |
OE |
$65.65 |
$1,969,500 |
D/D |
30,000 |
39,311 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2019-12-09 |
4 |
AS |
$225.00 |
$1,125,000 |
D/D |
(5,000) |
33,416 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2019-12-09 |
4 |
OE |
$109.14 |
$545,700 |
D/D |
5,000 |
38,416 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2019-11-25 |
4 |
AS |
$220.00 |
$1,100,000 |
D/D |
(5,000) |
33,416 |
|
- |
|
3280 Records found
|
|
Page 29 of 132 |
|
|
4.77 (1.01%) 
